Preserved T-cell response in anti-CD20-treated multiple sclerosis patients following SARS-CoV-2 vaccination.

Simon FaissnerNeele HeitmannRicarda RohlingUlas CeylanMarielena BongertCarlos Plaza-SirventCorinna MarheineckeXiomara PedreiturriaIlya AyzenbergKerstin HellwigIngo SchmitzStephanie PfaenderRalf Gold

Published in: Therapeutic advances in neurological disorders (2022)

In summary, aCD20-treated patients have a reduced humoral immune response, depending on B cell repopulation, in accordance with preserved cellular immune response, suggesting partial cellular protection against SARS-CoV-2.

Keyphrases

immune response
sars cov
end stage renal disease
newly diagnosed
multiple sclerosis
ejection fraction
chronic kidney disease
prognostic factors
dendritic cells
patient reported outcomes
toll like receptor
respiratory syndrome coronavirus
white matter